TNFSF10 and neoplasm: TNF-related apoptosis-inducing ligand (TRAIL) is a promising future anticancer drug due to its tumor selectivity, almost in the absence of side effects in animal trials, and phases I and II clinical studies.5, 6 The intracellular apoptosis signal transduction initiated by TRAIL is well characterized and involves the TRAIL-death receptors, FADD (Fas-associated protein with death domain) as adapter protein and caspases.